| Health Care Equipment & Supplies Industry | Healthcare Sector | Victor Previn CEO | CXA Exchange | - ISIN |
| AU Country | 301 Employees | - Last Dividend | - Last Split | - IPO Date |
Nova Eye Medical Limited is a medical technology company specializing in the design, development, manufacture, marketing, and sales of surgical devices focused on the treatment of glaucoma. Operating on a global scale, including in Australia, the United States, Europe, and the Asia Pacific, the company aims to innovate in the field of ophthalmology. Initially founded as Ellex Medical Lasers Limited in 1970, it underwent a name change to Nova Eye Medical Limited in July 2020. With its headquarters in Kent Town, Australia, the company is dedicated to addressing the challenges of glaucoma, a leading cause of blindness worldwide, through advanced surgical solutions.
This innovative glaucoma surgical device is designed to reduce intraocular pressure in adult patients suffering from open-angle glaucoma. The technology embodies a minimally invasive approach, offering a safer and efficient alternative to traditional glaucoma surgeries.
As an advancement in canaloplasty microcatheter technology, iTrack Advance represents the state-of-the-art in precision and effectiveness for glaucoma treatment. It further exemplifies Nova Eye Medical's commitment to delivering cutting-edge solutions in eye care.
This glaucoma drainage device is targeted at patients dealing with severe or complex glaucoma cases. Molteno3 is engineered to provide long-term relief by facilitating the drainage of excess intraocular fluid, thus managing the internal eye pressure effectively.
2RT, standing for Retinal Rejuvenation Therapy, is a proprietary laser technology developed by Nova Eye Medical for the treatment of patients in the early to intermediate stages of age-related macular degeneration (AMD). This non-invasive treatment option marks a significant advancement in AMD care, potentially slowing or halting disease progression.